Skip to main content
Top

Diagnostic and prognostic utility of complete blood count-derived ratios in giant cell arteritis: a retrospective fast-track clinic cohort study

Published in:

Abstract

Early diagnosis and treatment of giant cell arteritis (GCA) can prevent complications like vision loss. Traditional inflammatory markers C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) lack specificity. Complete blood count (CBC) components (neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR)) are emerging biomarkers in autoimmune diseases, but their role in GCA remains unclear. To evaluate the clinical utility of CBC components in GCA diagnosis and prognosis. This retrospective study analyzed patients from the University of Washington’s GCA fast-track clinic (2017–2024). Biomarkers were assessed using ROC curves, Kaplan-Meier survival analysis, and Cox proportional hazards models. Predictive models were developed using LASSO, stepwise, and Firth’s penalized logistic regression, with data split into training and test sets. A total of 250 patients were included (119 GCA, 131 non-GCA). All CBC biomarkers were significantly associated with ESR and CRP, but correlation coefficients remained low, with the strongest correlation observed between monocytes and ESR (R = 0.55). CBC components showed moderate predictive ability for GCA diagnosis, vascular ultrasound (vUS) and temporal artery biopsy positivity, and mortality (area under the curve (AUC) range 0.5–0.694). Stepwise models integrating both CBC and inflammatory markers provided marginal improvements in predictive performance, with most models including one of each or, in some cases, NLR alone. A total of 23 patients died, with 13 deaths (10.9%) in the GCA group during a median follow-up of 2.45 years (1.17–42.25). In survival analyses, ESR and CRP lost significance after time-stratified adjustments, while PLR (hazard ratio (HR): 1.004, p = 0.018), NLR (HR: 1.082, p = 0.040), and MLR (HR: 3.655, p = 0.044) remained associated with mortality. The best mortality prediction model (AUC = 0.914) identified coronary artery disease, age at vUS, and time since first Rheumatology visit as key predictors. Diagnostic models reached an AUC of 0.920 based on vascular ultrasound, clinical suspicion, and American College of Rheumatology/European League Against Rheumatism classification, outperforming models based solely on inflammatory traditional inflammatory biomarkers or CBC parameters. Routine CBC-derived ratios showed independent associations with mortality and performed comparably to ESR and CRP for GCA diagnosis. Their integration into clinical models may offer a simple, low-cost strategy to support diagnostic and prognostic assessment, including in patients with normal inflammatory markers.
Title
Diagnostic and prognostic utility of complete blood count-derived ratios in giant cell arteritis: a retrospective fast-track clinic cohort study
Authors
Irene Carrión-Barberà
Christian Lood
Ryan D. Stultz
Jenna Thomason
Alison M. Bays
Publication date
01-12-2025
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 12/2025
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-025-06022-y
This content is only visible if you are logged in and have the appropriate permissions.
This content is only visible if you are logged in and have the appropriate permissions.

Keynote webinar | Spotlight on progress in colorectal cancer

On-demand video coming soon

CRC remains a major global health burden, but advances in screening, treatment, and lifestyle-based prevention continue to reshape clinical practice. Gain insights into how the latest research can be leveraged to optimize patient care across the CRC continuum.

Prof. Antoni Castells
Prof. Harpreet Wasan
Prof. Edward Giovannucci
Notify me

Keynote webinar | Spotlight on functional neurological disorder

FND perplexes and frustrates patients and physicians alike. Limited knowledge and insufficient awareness delays diagnosis and treatment, and many patients feel misunderstood and stigmatized. How can you recognize FND and what are the treatment options?

Prof. Mark Edwards
Watch now
Video
Image Credits
Colon cancer illustration/© (M) KATERYNA KON / SCIENCE PHOTO LIBRARY / Getty Images, Human brain illustration/© (M) CHRISTOPH BURGSTEDT / SCIENCE PHOTO LIBRARY / Getty Images